Effect of Dupilumab on the Host-Microbe interface in Atopic Dermatitis

Effect of Dupilumab on the Host-Microbe interface in Atopic Dermatitis
Recruiting
18 years - 75 years
All
Phase N/A
99 participants needed
1 Location

Brief description of study

Atopic dermatitis is a disease with dry, scaly, itchy skin. People with AD often have problems with repear bacterial and viral skin infections. There repeat infections are often caused by a specific bacteria known as. Staph aureus, or just staph. People with chronic AD often use long term topical or oral treatments to help control their disease symptoms. Using these medications over long periods of time can have effects on the body. For this reason, new treatment options are being researched, especially for patients whose symptoms are not controlled by existing medications.

Detailed description of study

Dupilmab is a new treatment recently approved by the FDA. It is for the treatment of moderate-to-severe AD in adults whose AD symptoms are not well controlled with topical medications. The purpose of this study is to determine how dupilmab affects the amount of bacteria on the skin, the skin's water loss and the immune symptom.

This study will enroll participants between 18-75 yrs old. All participants will have chronic moderate to severe atopic dermatitis. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: atopic dermatitius,skin,dermatology
  • Age: 18 years - 75 years
  • Gender: All

This study will enroll participants between 18-75 yrs old. All participants will have chronic moderate to severe atopic dermatitis. 

Updated on 19 Feb 2024. Study ID: 831455

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.